Considering results from SARIL-RA-TARGET, SARIL-RA-MOBILITY, EXTEND, and MONARCH, how do you differentiate among agents and patients to identify ideal candidates for this IL-6 inhibitor vs. others?

Considering results from SARIL-RA-TARGET, SARIL-RA-MOBILITY, EXTEND, and MONARCH, how do you differentiate among agents and patients to identify ideal candidates for this IL-6 inhibitor vs. others?

Considering the positive results from the SARIL-RA-TARGET, SARIL-RA-MOBILITY and EXTEND studies, as well as the recently reported MONARCH study, how do you differentiate among the agents and RA patients to identify ideal candidates for this IL-6 inhibitor vs. others? What factors would you consider? How would you choose?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine University of Texas Southwestern Medical Center at Dallas Co-Director, Division of Rheumatology Texas Health Presbyterian Medical Center and Co-Medical Director Metroplex Clinical Research Center